New and emerging radiosensitizers and radioprotectors

Cancer Investigation

Volumn 24, Issue 4, 2006, Pages 444-456

  Spalding, Aaron ^a   Lawrence, Theodore ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Radiation; Radioprotection; Radiosensitization

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; ERLOTINIB; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; TEMOZOLOMIDE; TIRAPAZAMINE; TRASTUZUMAB;

ANEMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG MECHANISM; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; RADIATION PROTECTION; RADIATION RESPONSE; RADIOCHEMOTHERAPY; RADIOSENSITIZATION; RECTUM CANCER; REVIEW; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS;

EID: 33745311283     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705706     Document Type: Review

References (155)

1. Bernier, J.; Domenge, C.; Ozsahin, M.; Matuszewska, K.; Lefebvre, J.L.; et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350, 1945-1952.
2. Cooper, J.S.; Pajak, T.F.; Forastiere, A.A.; Jacobs, J.; Campbell, B.H.; et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004, 350, 1937-1944.
3. Brizel, D.M.; Albers, M.E.; Fisher, S.R.; Scher, R.L.; Richtsmeier, W.J.; et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 1998, 338, 1798-1804.
4. Forastiere, A.A.; Goepfert, H.; Maor, M.; Pajak, T.F.; Weber, R.; et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 2003, 349, 2091-2098.
5. Pearcey, R.; Brundage, M.; Drouin, P.; Jeffrey, J.; Johnston, D.; et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 2002, 20, 966-972.
6. Peters, W.A.; 3rd, Liu, P.Y.; Barrett, R.J.; 2nd, Stock, R.J.; Monk, B.J.; et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2000, 18, 1606-1613.
7. Morris, M.; Eifel, P.J.; Lu, J.; Grigsby, P.W.; Levenback, C.; et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 1999, 340, 1137-1143.
8. Keys, H.M.; Bundy, B.N.; Stehman, F.B.; Muderspach, L.I.; Chafe, W.E.; et al. Cisplatin radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 1999, 340, 1154-1161.
9. Rose, P.G.; Bundy, B.N.; Watkins, E.B.; Thigpen, J.T.; Deppe, G.; et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 1999, 340, 1144-1153.
10. Whitney, C.W.; Sause, W.; Bundy, B.N.; Malfetano, J.H.; Hannigan, E.V.; et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 1999, 17, 1339-1348.
11. Cooper, J.S.; Guo, M.D.; Herskovic, A.; Macdonald, J.S.; Martenson, J.A. Jr.; et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. Jama 1999, 281, 1623-1627.
12. Urba, S.G.; Orringer, M.B.; Turrisi, A.; Iannettoni, M.; Forastiere, A.; et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 2001, 19. 305-313.
13. Macdonald, J.S.; Smalley, S.R.; Benedetti, J.; Hundahl, S.A.; Estes, N.C.; et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001, 345, 725-730.
14. Sause, W.; Kolesar, P.; Taylor, S.I.; Johnson, D.; Livingston, R.; et al. 3rd Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000, 117, 358-364.
15. Dillman, R.O.; Herndon, J.; Seagren, S.L.; Eaton, W. L. Jr.; Green, M.R. et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer. Inst. 1996, 88, 1210-1215.
16. Krook, J.E.; Moertel, C.G.; Gunderson, L.L.; Wieand, H.S.; Collins, R.T.; et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 1991, 324, 709-715.
17. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N. Engl. J. Med. 1985, 312, 1465-1472.
18. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet 1996, 348, 1049-1054.
19. Bartelink, H.; Roelofsen, F.; Eschwege, F.; Rougier, P.; Bosset, J.F.; et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a Phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J. Clin. Oncol. 1997, 15, 2040-2049.
20. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
21. Yeo, T.P.; Hruban, R.H.; Leach, S.D.; Wilentz, R.E.; Sohn, T.A.; et al. Pancreatic cancer. Curr. Probl. Cancer 2002, 26, 176-275.
22. Muler, J.H.; McGinn, C.J.; Normolle, D.; Lawrence, T.; Brown, D.; et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J. Clin. Oncol. 2004, 22, 238-243.
23. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987, 59, 2006-2010.
24. Kolesnick, R.; Fuks, Z. Radiation and ceramide-induced apoptosis. Oncogene 2003, 22, 5897-5906.
25. Cao, Y.; Tsien, C.I.; Shen, Z.; Tatro, D.S.; Ten Haken, R.; et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J. Clin. Oncol. 2005, 23, 4127-4136.
26. Lawrence, T.S.; Blackstock, A.W.; McGinn, C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003, 13, 13-21.
27. Blackstock, A.W.; Kwock, L.; Branch, C.; Zeman, E.M.; Tepper, J.E. Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36, 641-648.
28. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
29. Cooper, J.S.; Ang, K.K. Concomitant chemotherapy and radiation therapy certainly improves local control. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 7-9.
30. Argiris, A.; Haraf, D.J.; Kies, M.S.; Vokes, E.E. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 2003, 8, 350-360.
31. Jeremic, B.; Shibamoto, Y.; Milicic, B.; Nikolic, N.; Dagovic, A.; et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. 2000, 18, 1458-1464.
32. Morganti, A.G.; Trodella, L.; Valentini, V.; Macchia, G.; Alfieri, S.; et al. Concomitant gemcitabine (Gemzar) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: a Phase I study. Onkologie 2003, 26325-329.
33. Crane, C.H.; Janjan, N.A.; Evans, D.B.; Wolff, R.A.; Ballo, M.T.; et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int. J. Pancreatol. 2001, 29, 9-18.
34. Tallarida, R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 2001, 298, 865-872.
35. Steel, G.G.; Peckham, M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5, 85-91.
36. Tozer, G.M.; Kanthou, C.; Baguley, B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
37. Nagy, A.; Schally, A.V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr. Pharm. Des. 2005, 11, 1167-1180.
38. Nicholson, R.I.; Hutcheson, I.R.; Britton, D.; Knowlden, J.M.; Jones, H.E.; et al. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J. Steroid. Biochem. Mol. Biol. 2005, 93, 257-262.
39. Liu, E.T. Expression genomics and drug development: towards predictive pharmacology. Brief Funct. Genomic Proteomic. 2005, 3, 303-321.
40. O'Hanlon, L.H. Deep-sea creatures yield treasure trove of cancer drugs. Nat. Med. 2005, 11, 698.
41. Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 2003, 3, 330-338.
42. Thomas, D.M.; Zalcberg, J.R. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin. Exp. Pharmacol. Physiol. 1998, 25, 887-895.
43. Willett, C.G. Radiation dose escalation in combined-modality therapy for esophageal cancer. J. Clin. Oncol. 2002, 20, 1151-1153.
44. Willett, C.G. Results of radiation therapy in gastric cancer. Semin. Radiat. Oncol. 2002, 12, 170-175.
45. Fogelman, D.R.; Chen, J.; Chabot, J.A.; Allendorf, J.D.; Schrope, B.A.; et al. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg. Oncol. Clin. N. Am. 2004, 13, 711-735.
46. Zhu, A.X.; Willett, C.G. Combined modality treatment for rectal cancer. Semin. Oncol. 2005, 32, 103-112.
47. Eifel, P.J. Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiat. Res. 2000, 154, 229-236.
48. Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 1987, 34, 155-166.
49. Huncharek, M.; McGarry, R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 2004, 9, 665-672.
50. Rodel, C.; Weiss, C.; Sauer, R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin. Radiat. Oncol. 2005, 15, 28-35.
51. Haddad, R.; Tishler, R.B.; Norris, C.M.; Mahadevan, A.; Busse, P.; et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 2003, 8, 35-44.
52. Fanucchi, M.; Khuri, F.R. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin. Oncol. 2004, 31, 809-815.
53. Rich, T.A.; Shepard, R.C.; Mosley, S.T. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J. Clin. Oncol. 2004, 22, 2214-2232.
54. O'Reilly, E.M.; Ilson, D.H. Cisplatin and irinotecan in upper gastrointestinal malignancies. Oncology (Huntingt) 2001, 15, 42-45.
55. Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Reed, E.; et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. 1996, 52, 1855-1865.
56. Pendyala, L.; Kidani, Y.; Perez, R.; Wilkes, J.; Bernacki, R.J.; et al. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett. 1995, 97, 177-184.
57. Mamenta, E.L.; Poma, E.E.; Kaufmann, W.K.; Delmastro, D.A.; Grady, H.L.; et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994, 54, 3500-3505.
58. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938-2947.
59. Freyer, G.; Bossard, N.; Romestaing, P.; Mornex, F.; Chapet, O.; et al. Addition of oxaliplatin to continuous fluorouracil, I-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 Phase I trial. J. Clin. Oncol. 2001, 19, 2433-2438.
60. Aschele, C.; Friso, M.L.; Pucciarelli, S.; Lonardi, S.; Sartor, L.; et al. A Phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann. Oncol. 2005, 16, 1140-1146.
61. Carraro, S.; Roca, E.L.; Cartelli, C.; Rafailovici, L.; Castillo Odena, S.; et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a Phase II IATTGI study. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 397-402.
62. Ryan, D.N.; D. Hollis, D.R.; Miedema, B.W.; Wadler, S.; Tepper, J.E.; et al. A Phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901. In: Proc ASCO 2004.
63. Rosenthal, D.I.; Catalano, P.; Haller, D.G.; Landry, J.C.; Sigurdson, E.R.; et al. A Phase I Study of Preoperative Radiation Therapy (RT) with Concurrent Protracted Continous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, Adjuvant 5-FU, and Leucovorin for Locally Advanced (T3/4) Rectal Adenocarcinoma [abstract]. In: Proc ASCO 2003.
64. Shewach, D.S.; Lawrence, T.S. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin. Oncol. 1995, 22, 68-71.
65. Lawrence, T.S.; Chang, E.Y.; Hahn, T.M.; Shewach, D.S. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin. Cancer Res. 1997, 3, 777-782.
66. Latz, D.; Fleckenstein, K.; Eble, M.; Blatter, J.; Wannenmacher, M.; et al. Radiosensitizing potential of gemcitabine (2′,2′-difluoro- 2′-deoxycytidine) within the cell cycle in vitro. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41, 875-882.
67. Wachters, F.M.; van Putten, J.W.; Maring, J.G.; Zdzienicka, M.Z.; Groen, H.J.; et al. Selective targeting of homologous DNA recombination repair by gemcitabine. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57, 553-562.
68. Robinson, B.W.; Im, M.M.; Ljungman, M.; Praz, F.; Shewach, D.S. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res. 2003, 63, 6935-6941.
69. Eisbruch, A.; Shewach, D.S.; Bradford, C.R.; Littles, J.F.; Teknos, T.N.; et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a Phase I trial and intracellular drug incorporation study. J. Clin. Oncol. 2001, 19, 792-799.
70. Blackstock, A.W.; Bernard, S.A.; Richards, F.; Eagle, K.S.; Case, L.D.; et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J. Clin. Oncol. 1999, 17, 2208-2212.
71. Crane, C.H.; Antolak, J.A.; Rosen, II, Forster, K.M.; Evans, D.B.; Janjan, N.A.; et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int. J. Gastrointest Cancer 2001, 30, 123-132.
72. Willett, C.G.; Czito, B.G.; Bendell, J.C.; Ryan, D.P. Locally advanced pancreatic cancer. J. Clin. Oncol. 2005, 23, 4538-4544.
73. McGinn, C.J.; Zalupski, M.M.; Shureiqi, I.; Robertson, J.M.; Eckhauser, F.E.; et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2001, 19, 4202-4208.
74. Kent, E.; Sandler, H.; Montie, J.; Lee, C.; Herman, J.; et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a Phase I trial. J. Clin. Oncol. 2004, 22, 2540-2545.
75. Suh, W.W.; Schott, A.F.; Hayman, J.A.; Schipper, M. J.; Shewach, D.S.; et al. A Phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences. Breast. J. 2004, 10, 204-210.
76. Vokes, E.E.; Herndon, J.E.; 2nd, Crawford, J.; Leopold, K.A.; Perry, M.C.; et al. Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage INB non-small-cell lung cancer: cancer and leukemia group B study 9431. J. Clin. Oncol. 2002, 20, 4191-4198.
77. Kim, J.S.; Amorino, G.P.; Pyo, H.; Cao, Q.; Choy, H. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother. Oncol. 2002, 62, 61-67.
78. Chakravarthy, A.; Choy, H. A Phase I trial of outpatient weekly irinotecan/carboplatin and concurrent radiation for stage III unresectable non small-cell lung cancer: a Vanderbilt-Ingram Cancer Center Affiliate Network Trial. Clin. Lung Cancer 2000, 1, 310-311.
79. Yamada, M.; Kudoh, S.; Fukuda, H.; Nakagawa, K.; Yamamoto, N.; et al. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br. J. Cancer 2002, 87, 258-263.
80. Brenner, B.; Ilson, D.H.; Minsky, B.D.; Bains, M.S.; Yong, W.; et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J. Clin. Oncol. 2004, 22, 45-52.
81. Mehta, V.K.; Cho, C.; Ford, J.M.; Jambalos, C.; Poen, J.; et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55, 132-137.
82. Kirichenko, A.V.; Rich, T.A.; Newman, R.A.; Travis, E.L. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer Res. 1997, 57, 1929-1933.
83. Denny, B.J.; Wheelhouse, R.T.; Stevens, M.F.; Tsang, L.L.; Slack, J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994, 33, 9045-9051.
84. Jansen, M.; Bardenheuer, W.; Sorg, U.R.; Seeber, S.; Flasshove, M.; et al. Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones. Eur. J. Haematol 2001, 67, 2-13.
85. Lonardi, S.; Tosoni, A.; Brandes, A.A. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat. Rev. 2005, 31, 79-89.
86. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol. 2001, 19, 509-518.
87. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352997-1003.
88. Koukourakis, M.I.; Giatromanolaki, A.; Fountzilas, G.; Sivridis, E.; Gatter, K.C.; et al. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin. Cancer Res. 2000, 6, 381-389.
89. Dunst, J.; Reese, T.; Sutter, T.; Zuhlke, H.; Hinke, A.; et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J. Clin. Oncol. 2002, 20, 3983-3991.
90. Crane, C.H.; Sargent, D.J. Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? J. Clin. Oncol. 2004, 22, 2978-2981.
91. Kim, J.C.; Kim, T.W.; Kim, J.H.; Yu, C.S.; Kim, H.C.; et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005.
92. Hofheinz, R.D.; von Gerstenberg-Helldorf, B.; Wenz, F.; Gnad, U.; Kraus-Tiefenbacher, U.; et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J. Clin. Oncol. 2005, 23, 1350-1357.
93. Corvo, R.; Pastrone, I.; Scolaro, T.; Marcenaro, M.; Berretta, L.; et al. Radiotherapy and oral capecitabine in the preoperative treatment of patients with rectal cancer: rationale, preliminary results and perspectives. Tumori 2003, 89, 361-367.
94. Cassidy, J.S.; W. McKendrick, J.; Kröning, H.; Nowacki, M.P.; Seitz, J.F.; et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a Phase III trial. In: Proc ASCO 2004.
95. Brown, J.M.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
96. McKeown, S.R.; Friery, O.P.; McIntyre, I.A.; Hejmadi, M.V.; Patterson, L.H.; et al. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br. J. Cancer Suppl. 1996, 27, S39-42.
97. Rischin, D.; Peters, L.; Hicks, R.; Hughes, P.; Fisher, R.; et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 535-542.
98. Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 2005, 23, 79-87.
99. Zhao, J.; Kim, J.E.; Reed, E.; Li, Q.Q. Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int. J. Oncol. 2005, 27, 247-256.
100. Tishler, R.B.; Geard, C.R.; Hall, E.J.; Schiff, P.B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992, 52, 3495-3497.
101. Tishler, R.B.; Schiff, P.B.; Geard, C.R.; Hall, E.J. Taxol: a novel radiation sensitizer. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 613-617.
102. Chen, Y.; Pandya, K.; Keng, P.P.; Feins, R.; Raubertas, R.; et al. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy. Am J. Clin. Oncol. 2001, 24, 432-437.
103. Herscher, L.L.; Hahn, S.M.; Kroog, G.; Pass, H.; Temeck, B.; et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J. Clin. Oncol. 1998, 16, 635-641.
104. Lau, D.; Leigh, B.; Gandara, D.; Edelman, M.; Morgan, R.; et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium Phase II trial. J. Clin. Oncol. 2001, 19, 442-447.
105. Choy, H.; Akerley, W.; Safran, H.; Graziano, S.; Chung, C.; et al. Multiinstitutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 1998, 16, 3316-3322.
106. Choy, H.; Safran, H.; Akerley, W.; Graziano, S.L.; Bogart, J.A.; et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin. Cancer Res. 1998, 4, 1931-1936.
107. Rosenthal, D.I.; Okani, O.; Corak, J.; Kavanaugh, D.; Kamen, B.; et al. Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a Phase I study. Semin. Oncol. 1997, 24, S12-96-S12-100.
108. Chen, Y.; Pandya, K.; Keng, P.C.; Johnstone, D.; Li, J.; et al. Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin. Cancer Res. 2003, 9, 969-975.
109. Suntharalingam, M.; Haas, M.L.; Conley, B.A.; Egorin, M.J.; Levy, S.; et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47 49-56.
110. Tishler, R.B.; Norris, C.M.; Jr.; Colevas, A.D.; Lamb, C.C.; Karp, D.; et al. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 2002, 95, 1472-1481.
111. Harari, P.M.; Huang, S.M. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 976-983.
112. Di Fiore, P.P.; Pierce, J.H.; Kraus, M.H.; Segatto, O.; King, C.R.; et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237, 178-182.
113. Pegram, M.D.; Konecny, G.; Slamon, D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res. 2000, 103, 57-75.
114. Guo, G.; Wang, T.; Gao, Q.; Tamae, D.; Wong, P.; et al. Expression of ErbB2 enhances radiation-induced NF-kappaB activation. Oncogene 2004, 23, 535-545.
115. Sartor, C.G.; M. Carey, L.; Dees, E.C.; Ollila, D.; Sherron, R.; et al. RADIOSENSITIZATION OF LOCALLY ADVANCED BREAST CANCER WITH HERCEPTIN - INITIAL TOXICITY RESULTS OF A PHASE II TRIAL. In: San Antonio Breast Cancer Meeting 2003.
116. Safran, H.; DiPetrillo, T.; Nadeem, A.; Steinhoff, M.; Tantravahi, U.; et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a Phase I study. Cancer Invest. 2004, 22, 670-677.
117. Huang, S.M.; Harari, P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000, 6, 2166-2174.
118. Raben, D.; Helfrich, B.; Chan, D.C.; Ciardiello, F.; Zhao, L.; et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 2005, 11, 795-805.
119. Milas, L.; Fan, Z.; Andratschke, N.H.; Ang, K.K. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 966-971.
120. Buchsbaum, D.J.; Bonner, J.A.; Grizzle, W.E.; Stackhouse, M.A.; Carpenter, M.; et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 1180-1193.
121. Maurizi, M.; Almadori, G.; Ferrandina, G.; Distefano, M.; Romanini, M.E.; et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer 1996, 74, 1253-1257.
122. Bentzen, S.M.; Atasoy, B.M.; Daley, F.M.; Dische, S.; Richman, P.I.; et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J. Clin. Oncol. 2005, 23, 5560-5567.
123. Robert, F.; Ezekiel, M.P.; Spencer, S.A.; Meredith, R.F.; Bonner, J.A.; et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 3234-3243.
124. Shin, D.M.; Donato, N.J.; Perez-Soler, R.; Shin, H.J.; Wu, J.Y.; et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 2001, 7, 1204-1213.
125. Bonner, J.G.; J. Harari, P.; et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. In: ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004.
126. Safran, H. Personal Communication, 2005.
127. She, Y.; Lee, F.; Chen, J.; Haimovitz-Friedman, A.; Miller, V.A.; et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin. Cancer Res. 2003, 9, 3773-3778.
128. Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Janne, P.A.; Kocher, O.; et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352, 786-792.
129. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13306-13311.
130. Sordella, R.; Bell, D.W.; Haber, D.A.; Settleman, J. Gefitinib- sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
131. Chinnaiyan, P.; Huang, S.; Vallabhaneni, G.; Armstrong, E.; Varambally, S.; et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005, 65, 3328-3335.
132. Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57, 4838-4848.
133. Akita, R.W.; Sliwkowski, M.X. Preclinical studies with Erlotinib (Tarceva). Semin. Oncol. 2003, 30, 15-24.
134. Higgins, B.; Kolinsky, K.; Smith, M.; Beck, G.; Rashed, M.; et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004, 15, 503-512.
135. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
136. Crane, C.E.; Abbruzzese, L.M.; Douglas, J.L.; Henry, E.B.; Ho, X.; et al. Phase I Trial of Bevacizumab (BV) with Concurrent Radiotherapy (RT) and Capecitabine (CAP) in Locally Advanced Pancreatic Adenccarcinoma (PA). In: Proc ASCO 2005.
137. Russo, S.M.; Tepper, J.E.; Baldwin, A.S.; Jr.; Liu, R.; Adams, J.; et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 183-193.
138. Van Waes, C.; Chang, A.A.; Lebowitz, P.F.; Druzgal, C.H.; Chen, Z.; et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2005.
139. Symon, Z.; Levi, M.; Ensminger, W.D.; Smith, D.E.; Lawrence, T.S. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 473-478.
140. Komaki, R.; Lee, J.S.; Milas, L.; Lee, H.K.; Fossella, F.V.; et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 2004, 55, 1369-1377.
141. Movsas, B.; Scott, C.; Langer, C.; Werner-Wasik, M.; Nicolaou, N.; et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J. Clin. Oncol. 2005, 23, 2145-2154.
142. De Los Santos, J.F.; Small, W. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions. Semin. Oncol. 2004, 31, 37-41.
143. Ben-Josef, E.; Han, S.; Tobi, M.; Vargas, B.J.; Stamos, B.; et al. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin Radiat. Oncol. 2002, 12, 81-85.
144. Menard, C.; Camphausen, K.; Muanza, T.; Sears-Crouse, N.; Smith, S.; et al. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results. Semin. Oncol. 2003, 30, 63-67.
145. Prosnitz, R.G.; Yao, B.; Farrell, C.L.; Clough, R.; Brizel, D.M. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 1087-1095.
146. Fazekas, J.T.; Scott, C.; Marcial, V.; Davis, L.W.; Wasserman, T.; et al. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79-15. Int. J. Radiat. Oncol. Biol. Phys. 1989, 17, 1177-1181.
147. van Acht, M.J.; Hermans, J.; Boks, D.E.; Leer, J.W. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal
148. Rudat, V.; Stadler, P.; Becker, A.; Vanselow, B.; Dietz, A.; et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol. 2001, 177, 462-468.
149. Brizel, D.M.; Dodge, R.K.; Clough, R.W.; Dewhirst, M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999, 53, 113-117.
150. Fyles, A.W.; Milosevic, M.; Pintilie, M.; Syed, A.; Hill, R.P. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol. 2000, 57, 13-19.
151. Henke, M.; Laszig, R.; Rube, C.; Schafer, U.; Haase, K.D.; et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003, 362, 1255-1260.
152. Lai, S.Y.; Childs, E.E.; Xi, S.; Coppelli, F.M.; Gooding, W.E.; et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005, 24, 4442-4449.
153. Belenkov, A.I.; Shenouda, G.; Rizhevskaya, E.; Cournoyer, D.; Belzile, J.P.; et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol. Cancer Ther. 2004, 3, 1525-1532.
154. Presant, C.A.; Wolf, W.; Albright, M.J.; Servis, K. L.; Ring, R.; 3rd, et al. Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol. 1990, 8, 1868-1873.
155. Ferguson, K.M. Active and inactive conformations of the epidermal growth factor receptor. Biochem. Soc. Trans. 2004, 32, 742-745.